Noggin, Human
Noggin, Human

Measured by its ability to inhibit BMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED50 for this effect is 4-80 ng/mL in the presence of 50 ng/mL of recombinant Human BMP‑4.

Noggin, Human

The purity of Noggin, Human is greater than 95% as determined by SEC-HPLC.

Noggin, Human

Noggin, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Noggin, Human

Noggin is an antagonist of bone morphogenetic proteins (BMP), being indispensable for certain developmental events.Noggin expression positively correlated with EGFR expression in both GC cell line models and The Cancer Genome Atlas human GC cohort. Targeting EGFR and its downstream pathways diminished cell proliferation which was promoted by Noggin. Noggin promotes the proliferation of GC cells by upregulating EGFR and enhancing a vicious circle formed by β‑catenin, EGFR, ERK and Akt.
Z05699
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
Noggin (Gln28-Cys232)_x000D_
Accession # Q13253
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 0.05EU per μg by the LAL method.
Biological Activity Measured by its ability to inhibit BMP­4­induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. Test result was comparable to standard batch.
Expression System CHO
Theoretical Molecular Weight 23.05 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 30-36 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • Noggin, Human
    • Noggin, Human

    Measured by its ability to inhibit BMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED50 for this effect is 4-80 ng/mL in the presence of 50 ng/mL of recombinant Human BMP‑4.

  • Noggin, Human
    • Noggin, Human

    The purity of Noggin, Human is greater than 95% as determined by SEC-HPLC.

  • Noggin, Human
    • Noggin, Human

    Noggin, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Noggin is an antagonist of bone morphogenetic proteins (BMP), being indispensable for certain developmental events.Noggin expression positively correlated with EGFR expression in both GC cell line models and The Cancer Genome Atlas human GC cohort. Targeting EGFR and its downstream pathways diminished cell proliferation which was promoted by Noggin. Noggin promotes the proliferation of GC cells by upregulating EGFR and enhancing a vicious circle formed by β‑catenin, EGFR, ERK and Akt.
Synonyms Noggin; NOG; SYM1; SYNS1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.